Relevant bibliographies by topics / % and 2% ketoconazole

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic '% and 2% ketoconazole'

Author: Grafiati
Published: 7 June 2025
Last updated: 17 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '% and 2% ketoconazole.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "% and 2% ketoconazole"

1

Scheinfeld, Noah S. "Xolegel (ketoconazole, 2%)." SKINmed 5, no. 5 (2006): 241. http://dx.doi.org/10.1111/j.1540-9740.2006.05928.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hameed, Sadia, Mohammad Majid Paracha, Farah Sagheer, Abdul Qayum Khan, and Sahibzada Mahmood Noor. "COMPARATIVE STUDY OF EFFICACY OF COMBINED TREATMENT WITH KETOCONAZOLE 2% CREAM AND ADAPALENE 0.1% GEL VS. KETOCONAZOLE 2% CREAM MONOTHERAPY IN PITYRIASIS VERSICOLOR." American Journal of Health, Medicine and Nursing Practice 7, no. 6 (2022): 33–40. http://dx.doi.org/10.47672/ajhmn.1029.

Full text
Abstract:
Background: Pityriasis Versicolor (PV) is an infection of the superficial layers of skin caused by Malassezia yeasts. It is a non-contagious disease characterized by hypo and hyperpigmented macules on the body. Up to 40% of people face itching, decreased quality of life, social stigmatization, and embarrassment due to the lesions. Adapalene with Ketoconazole provides an efficient option for PV patients due to better toxicity profile and rapid action on the lesions.
 Objective: Comparison of efficacy of combined therapy with Ketoconazole 2% cream and adapalene 1% gel against Ketoconazole 2% cream monotherapy in Pityriasis Versicolor.
 Methods: Total 90 patients (45 in each group) were included in the study. Group-A was treated with combination of Ketoconazole 2% cream & adapalene 1% gel while group-B was given Ketoconazole 2% cream monotherapy. Study design was randomized controlled trial and SPSS version 26 was used for data analysis.
 Results: Mean age of the patients was 24.3±4.3 and 23.3±3.9 years in group-A and B, respectively. There were 30 males (66.7%) & 15 females (33.3%) in group-A while 35 males (77.8%) and 10 females (22.2%) in group-B. Mean duration of disease was 2.0±0.9 months in group-A & 2.3±1.2 months in group-B.The efficacy of combined therapy with Ketoconazole 2% cream & adapalene 1% gel was found to be better when compared with Ketoconazole 2% cream monotherapy in Pityriasis Versicolor. Difference between two groups (p=0.011) was statistically significant.
 Conclusion: It was concluded that adapalene 0.1% gel & ketoconazole 2% cream in combination is more effective than ketoconazole 2% cream monotherapy in the treatment of PV.
 Recommendation: It is recommended to use a combination of adapalene 0.1% gel & ketoconazole 2% cream than ketoconazole 2% cream monotherapy in the treatment of PV.
 
APA, Harvard, Vancouver, ISO, and other styles
3

Kajal, Kosankar* Kamlesh Deore Sakshi Chavan Vaishnavi More Simran Chaudhari Komal Gawali. "Evaluation Of 1% And 2% Ketoconazole Shampoo." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 466–78. https://doi.org/10.5281/zenodo.15334729.

Full text
Abstract:
Ketoconazole shampoo, an effective antifungal treatment, is widely used to combat dandruff, seborrheic dermatitis, and various other fungal infections. The active ingredient, ketoconazole, halts the growth of Malassezia, a common fungus associated with these scalp issues. Available in two strengths, 1% and 2%, the shampoo can be purchased over-the-counter in its 1% form, while the 2% formulation usually requires a prescription. These varying strengths cater to different levels of severity, with the 1% option being particularly popular for mild to moderate cases due to its accessibility and minimal side effects. Originally developed by Janssen Pharmaceutica in the 1970s, ketoconazole began as an oral antifungal medication targeting systemic infections. Recognizing its efficacy in treating fungal scalp conditions, researchers explored its potential in topical applications, leading to the creation of the shampoo in the early 1980s. The patent for ketoconazole was filed in 1977, and it soon became a staple in dermatological treatment, especially for conditions like seborrheic dermatitis and dandruff. These abstract outlines the development, historical background, and therapeutic uses of ketoconazole shampoo, highlighting its significance in treating fungal infections and scalp conditions. Its antifungal properties, along with the availability of both OTC and prescription versions, make ketoconazole shampoo a vital tool in managing dermatological health.
APA, Harvard, Vancouver, ISO, and other styles
4

HARMANYERİ, Yavuz, Coşkun ACAY, and Keramettin DOĞRUÖZ. "Seboreik Dermatit Tedavisinde, Topikal Ketokonazol Kullanımı." European Journal of Therapeutics 1, no. 1 (1990): 94–97. http://dx.doi.org/10.58600/eurjther.19900101-504.

Full text
Abstract:
in our study, twenty patients (7 females and 13 males) with seborrhoeic dermatitis of the scalp were treated, in three randomized groups, tor o maximum eight weeks, with 1 % hydrocortisone, 2 & ketoconazole or 2 % ketoconazole + 1 % hydrocortisone. Patients who treated theese drugs, were followed tor three months. At the and of this study, either 2 % ketoconazole or 2 % ketoconazole + 1 % hydrocortisone were significantly better than 1 % hydrocortisone.
APA, Harvard, Vancouver, ISO, and other styles
5

Khozeimeh, Faezeh, Omid Savabi, Mohammad Ali Shahtalebi, and Mojtaba Noori. "Comparative Evaluation of Ketoconazole Tablet and Topical Ketoconazole 2% in Orabase in Treatment of Candida-Infected Denture Stomatitis." Journal of Contemporary Dental Practice 11, no. 2 (2010): 17–24. http://dx.doi.org/10.5005/jcdp-11-2-17.

Full text
Abstract:
Abstract Aim Denture stomatitis is a common and recurring problem of denture wearers. Ketoconazole tablet is one of the antimycotic drugs that often has been used to treat this condition, but systemic use of this drug has some adverse effects that frequently lead to unfavorable compliance and treatment failure. This study was designed to compare the efficacy of topical ketoconazole 2% in orabase and ketoconazole tablet. Methods and Materials Thirty patients with denture stomatitis (positive culture) were divided into two groups. The first group received ketoconazole tablet (orally used 200 mg per day) for 14 days and the second group received 2% topical ketoconazole in orabase applied twice daily on the mucosal denture surface. Candida cultures were taken from the palatal mucosa before and on days 7 and 14 after commencement of the therapy. The mean of colonies before and 7 and 14 days after medication were calculated. Oneway ANOVA and paired t-test were used for data analysis (α=0.05). Results The mean of colonies number before receiving medication in the tablet and topical application groups were 454 and 441 respectively. The mean of colonies number after receiving medication in tablet and topical application group were 137 and 176 (on the seventh day) and 122 and 96 (on the 14th day), respectively; there was no significant difference between the two groups after medication (p=0.18). Conclusion Topical ketoconazole 2% in orabase can be useful in managing denture stomatitis. This topical medication has fewer side effects, whereas systemic administration of ketoconazole tablet is associated with some complications. Clinical Significance The application of topical ketoconazole 2% in orabase ointment can be considered in the treatment of denture stomatitis and has comparable efficacy with the ketoconazole tablet. Citation Khozeimeh F, Shahtalebi MA, Noori M, Savabi O. Comparative Evaluation of Ketoconazole Tablet and Topical Ketoconazole 2% in Orabase in Treatment of Candida-infected Denture Stomatitis. J Contemp Dent Pract [Internet]. 2010 March; 11(2):017-024. Available from: http://www.thejcdp.com/journal/view/volume11-issue2-khozeimeh.
APA, Harvard, Vancouver, ISO, and other styles
6

Kaeser, Benoite, Hagen Zandt, Fabrice Bour, Elke Zwanziger, Christophe Schmitt, and Xiaoping Zhang. "Drug-Drug Interaction Study of Ketoconazole and Ritonavir-Boosted Saquinavir." Antimicrobial Agents and Chemotherapy 53, no. 2 (2008): 609–14. http://dx.doi.org/10.1128/aac.00769-08.

Full text
Abstract:
ABSTRACT Saquinavir, a potent human immunodeficiency virus protease inhibitor, is extensively metabolized by CYP3A4. Saquinavir is coadministered with ritonavir, a strong CYP3A4 inhibitor, to boost its exposure. Ketoconazole is a potent CYP3A inhibitor. The objectives of this study were to investigate the effect of ketoconazole on the pharmacokinetics of saquinavir/ritonavir and vice versa using the approved dosage regimens of saquinavir/ritonavir at 1,000/100 mg twice daily and ketoconazole at 200 mg once daily. This was an open-label, randomized two-arm, one-sequence, two-period crossover study in healthy subjects. In study arm 1, 20 subjects received saquinavir/ritonavir treatment alone for 14 days, followed in combination with ketoconazole treatment for 14 days. In arm 2, 12 subjects received ketoconazole treatment for 6 days, followed in combination with saquinavir/ritonavir treatment for 14 days. The pharmacokinetics were assessed on the last day of each treatment (days 14 and 28 in arm 1 and days 6 and 20 in arm 2). The exposures C max and the area under the concentration-time curve from 0 to 12 h (AUC0-12) of saquinavir and ritonavir with or without ketoconazole were not substantially altered after 2 weeks of concomitant dosing with ketoconazole. The C max and AUC0-12 of ketoconazole, dosed at 200 mg once daily, were increased by 45% (90% confidence interval = 32 to 59%) and 168% (90% confidence interval = 146 to 193%), respectively, after 2 weeks of concomitant dosing with ritonavir-boosted saquinavir (1,000 mg of saquinavir/100 mg of ritonavir given twice daily). The greater exposure to ketoconazole when given in combination with saquinavir/ritonavir was not associated with unacceptable safety or tolerability. No dose adjustment for saquinavir/ritonavir (1,000/100 mg twice daily) is required when coadministered with 200 mg of ketoconazole once daily, and high doses of ketoconazole (>200 mg/day) are not recommended.
APA, Harvard, Vancouver, ISO, and other styles
7

Cam, Van Tran, Thuong Nguyen Van, Khang Tran Hau, et al. "Efficacy of Azole Antifungal in Treatment of Pityriasis Versicolor." Open Access Macedonian Journal of Medical Sciences 7, no. 2 (2019): 272–74. http://dx.doi.org/10.3889/oamjms.2019.092.

Full text
Abstract:
AIM: Compare itraconazole alone, fluconazole combined with ketoconazole and ketoconazole in the treatment of patients with pityriasis versicolor.
 MATERIAL AND METHODS: A group of 240 pityriasis versicolor patients (confirmed with KOH and culture) were classified into 3 groups: Fluconazole 300 mg a week and 2% ketoconazole foam twice a week for 2 weeks (Category I), Itraconazole 200 mg daily for one week (category II); Ketoconazole 2% foam daily for 2 weeks (Category 3). Clinical (colour of macule, scale, pruritus) and mycological assessment were done after 4 weeks of therapy.
 RESULTS: After 4 weeks of treatment, clinical cure was observed in 62.4% (Category I), 36.3% (Category II) and 37.5% (Category III).
 CONCLUSION: It was reported in our study that the most effective regimen for PV patients is fluconazole 300 mg per week combined with ketoconazole 2% twice a week for 2 weeks.
APA, Harvard, Vancouver, ISO, and other styles
8

Trang, Lê Thị Minh, Vũ Huy Lượng та Đỗ Thị Thu Hiền. "HIỆU QUẢ ĐIỀU TRỊ BỆNH VIÊM DA DẦU Ở ĐẦU BẰNG DẦU GỘI KETOCONAZOLE 2% KẾT HỢP CALCIPOTRIOL VÀ BETAMETHASONE BÔI TẠI CHỖ". Tạp chí Da liễu học Việt Nam 34 (16 червня 2022): 5–14. http://dx.doi.org/10.56320/tcdlhvn.v34i.27.

Full text
Abstract:
TÓM TẮT
 Mục tiêu: Đánh giá và so sánh hiệu quả điều trị bệnh viêm da dầu ở đầu mức độ trung bình đến rất nặng bằng dầu gội ketoconazole 2% kết hợp bôi tại chỗ calcipitriol và betamethasone với calcipitriol và betamethasone bôi tại chỗ đơn độc .
 Đối tượng và phương pháp: Thử nghiệm lâm sàng đối chứng ngẫu nhiên: 83 bệnh nhân viêm da dầu ở đầu mức độ từ trung bình đến rất nặng được phân ngẫu nhiên vào 2 nhóm: nhóm 1 sử dụng bôi tại chỗ calcipotriol và betamethasone kết hợp với dầu gội ketoconazol 2% trong 4 tuần sau đó duy trì dầu gội ketoconazole trong 4 tuần tiếp theo, nhóm 2 chỉ sử dụng Xamiol gel đơn độc trong 4 tuần. Thời gian theo dõi là 8 tuần.
 Kết quả: Sau 4 tuần điều trị, cả 2 nhóm đều cải thiện triệu chứng ngứa, đỏ da và vảy da rõ ràng. Tỷ lệ cải thiện mức độ bệnh trung bình của nhóm 1 và nhóm 2 lần lượt là 57,9% và 58,4% (p >0,05). Sau 8 tuần tỷ lệ cải thiện của nhóm 1 cao hơn có ý nghĩa so với nhóm chứng (58,1% so với 50,6%; p < 0,05), tỷ lệ tái phát của nhóm 1 thấp hơn có ý nghĩa so với nhóm chứng (21,4% so với 41,5%; p<0,05).
 Kết luận: thuốc bôi calcipotriol kết hợp betamethasone cho thấy có hiệu quả trong việc điều trị viêm da dầu ở đầu. Khi kết hợp với dầu gội chứa ketoconazole 2% làm giảm tỷ lệ tái phát.
APA, Harvard, Vancouver, ISO, and other styles
9

Assegaf, Tengku SDIS, Nelva K. Jusuf, Yunita S. Pane, et al. "Anti-dandruff effects of butterfly pea flowers (Clitoria ternatea)-based shampoo: A pretest-posttest control study." Narra J 4, no. 2 (2024): e876. http://dx.doi.org/10.52225/narra.v4i2.876.

Full text
Abstract:
Butterfly pea flower (Clitoria ternatea) may serve as an alternative anti-dandruff treatment; however, its effects on Malassezia spp. remain unexplored. The aim of this study was to explore the effects of C. ternatea as an herbal-based anti-dandruff treatment on Malassezia spp. DNA expression, plakoglobin levels, IL-8 levels, sebum levels, dandruff severity scores, adverse effects, and patient satisfaction. An experimental study with a pretest-posttest control design was conducted at Outpatient Clinic of Dermatology and Venereology, Arifin Achmad Hospital, Pekanbaru, Indonesia, from November 2023 to January 2024. The flower of C. ternatea was used to formulate the shampoo. The study involved 70 female patients aged 18–25 with dandruff, who were divided into two groups: (a) experimental group using 20% C. ternatea shampoo; and (b) control group using 2% ketoconazole shampoo. The present study found that 2% ketoconazole shampoo significantly reduced Malassezia spp. DNA expression compared to 20% C. ternatea shampooo (Clitoria ternatea: ΔCq=1.76±3.18; ketoconazole: ΔCq=3.77±2.90; p=0.008). No significant difference was observed in plakoglobin levels (C. ternatea: ΔCq=1.98±3.63; ketoconazole: ΔCq=2.50±2.36; p=0.427) or IL-8 levels (C. ternatea: ΔCq=3.46±4.00; ketoconazole: ΔCq=4.16 ± 3.62; p=0.459). C. ternatea significantly reduced sebum levels more than ketoconazole (C. ternatea: 1.16±0.98%; ketoconazole: 0.22±0.38%; p<0.001). Dandruff scores and patient satisfaction were similar for both shampoos (p=0.115 and p=0.336, respectively). Adverse effects were more common in the 2% ketoconazole shampoo group, affecting 21.2% of the patients. In conclusion, 2% ketoconazole shampoo is more effective in reducing Malassezia spp. DNA expression, while 20% C. ternatea shampoo offers better sebum control. Both shampoos are similarly effective in ameliorating dandruff severity and are well-tolerated, with fewer adverse effects reported for C. ternatea.
APA, Harvard, Vancouver, ISO, and other styles
10

Ketaren, Divanya Regatha, Suhartomi Suhartomi, Qori Fadillah, Joice Sonya Gani Panjaitan, Siti Syarifah, and Jenny Ria Sihombing. "PERBANDINGAN OBAT ANTI JAMUR KETOCONAZOLE DAN SALEP 2-4 PADA KASUS TINEA PEDIS DI TEMPAT PEMBUANGAN AKHIR SAMPAH TERJUN KOTA MEDAN." Kieraha Medical Journal 6, no. 2 (2024): 122–28. https://doi.org/10.33387/kmj.v6i2.9100.

Full text
Abstract:
Tinea Pedis merupakan salah satu infeksi jamur superfisial kulit yang paling umum di seluruh dunia yang bersifat menular dan berulang. Infeksi ini sering kali tertular secara kontak langsung dengan spora organisme penyebab atau bagian kulit yang terinfeksi. Prevalensi global tinea pedis diperkirakan sekitar 3% dengan risiko seumur hidup mencapai 70%. Prevalensi pada remaja dan dewasa lebih tinggi dibandingkan pada anak-anak. Kejadian tertinggi terjadi antara usia 16 dan 45 tahun saat aktivitas tinggi. Tujuan penelitian ini adalah untuk melihat perbandingan efektivitas antara obat anti jamur ketoconazole dengan Salep 2 - 4 yang mengandung salisilat dalam mengobati penyakit infeksi jamur di Tempat Pembuangan Akhir Sampah Terjun Kota Medan. Penelitian ini merupakan penelitian eksperimental uji klinis, yakni uji klinis acak terkontrol (Randomized Controlled Trial) yang dilakukan di Tempat Pembuangan Akhir Sampah Terjun Kota Medan sebanyak 32 pemulung dan petugas sampah, dibagi menjadi dua kelompok yaitu salep ketoconazole dan salep 2 - 4 dilakukan selama 14 hari dengan follow up pada hari ke - 4, 8, 14. Hasil pengobatan pada hari ke - 4 dengan angka kesembuhan salep ketoconazole (56.25%), salep 2-4 (18.75%) dengan nilai P = 0.028. Pada hari ke - 8 angka kesembuhan salep ketoconazole (68.75%) salep 2 - 4 (31.25%) dengan nilai P = 0.034. Pada hari ke – 14 angka kesembuhan salep ketoconazole (93.75%) salep 2-4 (56.25%) dengan nilai P = 0.037. Kesimpulan dari terdapat perbandingan efektivitas antara obat anti jamur ketoconazole dan salep 2-4 dalam mengobati infeksi jamur tinea pedis.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "% and 2% ketoconazole"

1

DECROUX, BRIGAUD PASCALE. "Efficacite du ketoconazole dans les syndromes de cushing paraneoplasiques : a propos de 2 cas personnels et 10 cas bibliographiques." Lyon 1, 1992. http://www.theses.fr/1992LYO1M071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yatabe, Rodríguez Kennosuke. "Manual de guías de trabajo para la elaboración de preparados magistrales y oficinales : elaboración de un champú de ketoconazol al 2%." Tesis, Universidad de Chile, 2007. http://www.repositorio.uchile.cl/handle/2250/105650.

Full text
Abstract:
Unidad de práctica para optar al título de Químico Farmacéutico<br>No autorizada por el autor para ser publicada a texto completo en el Portal de Tesis Electrónicas<br>La práctica prolongada en el Recetario Magistral de farmaLIDER se realizó durante seis meses, en este periodo de tiempo se trabajó en las distintas áreas de producción, bajo la supervisión de la Químico Farmacéutico Elizabeth Murgas, jefa de control de procesos en el Recetario Magistral, y con el apoyo del Químico Farmacéutico Waldo Sibo, jefe de operaciones del mismo. Con el objeto de asegurar uniformidad, consistencia, confianza en cada una de las actividades realizadas en el recetario, disminuir errores sistemáticos y proveer entrenamiento y guía para los auxiliares de farmacia, se redactó un Manual de guías de trabajo para la elaboración de 22 preparados magistrales y 2 productos oficinales. Además de redacción de las guías de trabajo, durante el período de práctica se observó que el champú a base de Ketoconazol al 2% elaborado en el Recetario Magistral adquiría una coloración rojiza. Para solucionar este inconveniente se hizo una revisión bibliográfica de las características del Ketoconazol y de las materias primas que permiten elaborar un champú base en el cual suspender el principio activo, con esta información, el champú a base de Ketoconazol al 2% no mostró la aparición de la coloración rojiza, manteniéndose estable físicamente a una temperatura ambiente.
APA, Harvard, Vancouver, ISO, and other styles
3

Buckholz, Cheryl J. "Acute bioactivation and hepatotoxicity of ketoconazole in rat and the determinant presence of flavin-containing monooxygenase (FMO) isoforms in human duodenum, jejunum, ileum, and colon microsomes and Caco-2 cell line." Thesis, 2003. http://hdl.handle.net/1957/31055.

Full text
Abstract:
Two specific goals were addressed for this dissertation. First to investigate and identify the mechanistic profile of ketoconazole (KT)-induced hepatotoxicity by utilizing in vivo and in vitro approaches determining the mechanism of action for the hepatotoxicity incurred. To date, there has not been a mechanistic determination of the hepatotoxicity associated with KT in vivo. This dissertation evaluates the possible metabolic bioactivation of KT by cytochrome-P450 (CYP) or flavin-containing monooxygenases (FMO) resulting in covalent binding with hepatic macromolecules. The hypothesis of this study was to reveal whether covalent binding by the parent compound, KT, and/or reactive metabolites produces hepatic damage associated with increased serum alanine aminotransaminase (ALT) release and decreased hepatic glutathione (GSH). The first objective was determination of in vivo covalent binding in a dose-time response comparison in Sprague-Dawley (SD) rat ALT and GSH levels. Increased ALT and reduced hepatic GSH levels occurred. The second objective was an in vitro comparison of covalent binding with GSH levels utilizing SD microsomal protein with incubations of KT. Covalent binding decreased with added GSH to microsomal incubations. Thirdly, correlate in vivo with in vitro findings. Covalent binding of KT in vivo and in vitro occurred with increased doses and time. The final objective was to determine the bioactivation pathway utilizing heat inactivation and no NADPH in vitro. Covalent binding of KT decreased in the absence of NADPH and deactivation of FMO. The second goal was to determine and quantitate in vitro the presence of FMO isozymes in microsomes of the human intestinal duodenum, jejunum, ileum, and colon as well as the Caco-2 (HTB-37), epithelial intestinal (CCL-241) and colon (CRL1790) cell lines. The presence of FMO could result in a first-pass effect decreasing the bioavailability of soft nucleophiles or a toxicity effect due to inhibition or modulation of the enzyme from co-administration. To date, this is the first evaluation of FMO isoforms in human intestine and cell lines. Western blot techniques were utilized for detection of human FMO1, FMO3, and FMO5 using human FMO-expressed recombinant cDNA from a baculovirus system.<br>Graduation date: 2003
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "% and 2% ketoconazole"

1

Dalley, D., and B. Brigham. "Phase I-II study of oral Etoposide and modulation of drug resistance with ketoconazole in small cell lung cancer." In Cancer Treatment An Update. Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_67.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Ketoconazole." In Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/00522-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Papich, Mark G. "Ketoconazole." In Saunders Handbook of Veterinary Drugs. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-24485-5.00327-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jew, Rita K., Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes. "Ketoconazole Suspension 20 mg/mL—Formulation 2." In Extemporaneous Formulations. ASHP, 2022. http://dx.doi.org/10.37573/9781585286522.085.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

H. Contreras, Patricio. "Berardinelli-Seip Syndrome: Report of an Old Case Successfully Treated with Anti-Glucocorticoid Therapy Followed by Bilateral Adrenalectomy." In Insulin Resistance and Lipodystrophy Syndromes - From Molecular Mechanisms to Treatment Strategies [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.102986.

Full text
Abstract:
A female teenager was diagnosed in 1986 with Berardinelli-Seip syndrome (congenital generalized lipodystrophy). Following the predictable failure of the usual treatments for her severe type 2 diabetes and hypertriglyceridemia, we decided to treat her with a novel anti-glucocorticoid-centered approach. In 1988, we treated her with mifepristone alone (9 weeks), then with mifepristone combined with ketoconazole (1 week), and again, with mifepristone alone (2 weeks). Acanthosis nigricans, as well as eruptive xanthomas, experienced complete regression following the anti-glucocorticoid therapy. Moreover, the patient gained 7 kilograms. Besides, there was a striking metabolic amelioration with mifepristone therapy. The addition of ketoconazole strongly reduced the relevant mifepristone-induced hypercortisolemia within 1 week. Fasting serum glucose, insulin, and triglycerides fell from day 1 to day 7 without reaching values within the normal range. Two weeks after ketoconazole withdrawal (while keeping mifepristone administration), serum triglyceride and glucose values rose significantly. Eleven days after bilateral adrenalectomy, fasting glucose values were within normal limits or slightly above. An oral glucose tolerance test (75-g OGTT) performed 13 days after surgery showed insulin values within normal limits, fasting serum glucose values within the normal range, and a 2-h serum glucose value in the diabetic range. These findings were consistent with our working hypothesis proposing that Berardinelli-Seip syndrome is due to cortisol-mediated unrestrained lipolysis.
APA, Harvard, Vancouver, ISO, and other styles
6

"KETOCONAZOLE INHIBITION OF 24-HYDROXYLASE ACTIVITY ENHANCES FUNCTIONAL RESPONSE TO l,2S(OH)2D3 IN CACO-2 CELLS." In Vitamin D. De Gruyter, 1991. http://dx.doi.org/10.1515/9783110850345-105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mokale, Vinod, Shivraj Naik, Trupti Khatal, Shirish H. Sonawane, and Irina Potoroko. "Formulation development and in vitro multimedia drug release study of solid self-microemulsifying drug delivery system of ketoconazole for enhanced solubility and pH-independent dissolution profile." In Encapsulation of Active Molecules and Their Delivery System. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-819363-1.00013-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "% and 2% ketoconazole"

1

Abalenikhina, Yulia, Elena A. Sudakova, Pelageya Erokhina, Aleksey Shchulkin, and Elena Yakusheva. "ROLE OF PREGNAN-X-RECEPTOR IN CELL RESISTANCE TO NITROSATIVE AND OXIDATIVE STRESS." In NEW TECHNOLOGIES IN MEDICINE, BIOLOGY, PHARMACOLOGY AND ECOLOGY. Institute of information technology, 2021. http://dx.doi.org/10.47501/978-5-6044060-1-4.47.

Full text
Abstract:
The article discusses the new role of pregnane X receptor (PXR) under conditions of oxidative and nitrosative stress. The results showed that the effect of hydrogen peroxide and S-nitrosoglu-tathione in high concentrations on Caco-2 cells leads to a decrease in cell viability, which is accompanied by an increase in the amount of PXR. These changes are offset by the addition of ketoconazole (inhibitor of PXR) to the medium.
APA, Harvard, Vancouver, ISO, and other styles
2

Zveaghintseva, Marina, Eughenia Stingaci, Serghei Pogrebnoi, Lucian Lupascu, Victor Kravtsov, and Fliur Macaev. "Inhanced antifungal activity with the joint use of dehydroabietinic acid and 2 tert-butyl-3-(1h-1,2,4-triazol-1-yl)-2h-chromene-2-ol." In Scientific seminar with international participation "New frontiers in natural product chemistry". Institute of Chemistry, Republic of Moldova, 2023. http://dx.doi.org/10.19261/nfnpc.2023.ab09.

Full text
Abstract:
The wide potential of resin acids as bioactive agents gave rise to a growing effort in the search for new applications of the natural forms and semisynthetic agents [1]. From the other hand, chromenes are widespread in natural products and have attracted much attention from a researchers in medicinal chemistry [2]. From the point of view of bioactivity, the hybrid system of 1,2,4-triazol and chromenol is an interesting subject for study [3].To obtain the co-crystalline particles of dehydroabietinic acid and 2-tert-butyl-3-(1H-1,2,4triazol-1-yl)-2H-chromen-2-ol, two different sets of conditions were tried: co-precipitation and the kneading method, which is relatively simple and consists of precisely weighing the acid and chromen 1, stirring and grinding them in the dry phase for a few minutes, followed by the addition of some H2O. The mixture of dehydroabietic acid and 2-tert-butyl-3-(1H-1,2,4-triazol-1-yl)-2H-chromene-2-ol becomes a paste that has been triturated for 1.5 hours and finally resulting product is dried. The antifungal activity of dehydroabietic acid, 2-tert-butyl-3-(1H-1,2,4-triazol-1-yl)-2Hchromene2-ol and microparticulate system was evaluated against different species: Candida albicans, Saccharomyces cerevisiae. Aspergillus fumigatus, A. versicolor, A. ochramensis, Trichoderma viride respectively. All the tested compounds exhibited good antifungal activity which was higher compared to the parent components and reference drugs (ketoconazole and bifonazole).
APA, Harvard, Vancouver, ISO, and other styles
3

Montana, Fajar Daniswara, Yuni Setyaningsih, and Fajriati Zulfa. "Effectiveness of Cocoa (Theobroma Cacao L.) Seed Extract on the Growth of in Vitro Malassezia Furfur." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.05.01.

Full text
Abstract:
ABSTRACT Background: Pityriasis versicolor or Tinea versicolor is a skin disease caused by the Malassezia furfur which is often found in Indonesia. People can use anti-fungal drugs to treat this disease. However, long-term use of anti-fungal drugs is relatively more expensive and can have side effects for its users. Cocoa bean husk contains flavonoids, saponins, and alkaloids which have anti-fungal effects. This study aimed to determine the antifungal effectiveness of the cocoa bean husk extract on the growth of M. furfur. Subjects and Methods: This was an experimental study using cocoa bean husk extract with a concentration variance of 25%, 50%, 75%, 100%, with a positive control for ketoconazole 2% and a negative control using distilled water. The test was carried out by the well diffusion method using Sabouraud Dextrose Agar media. The inhibition of fungal growth was calculated by looking at the clear zone formed after 48 hours. Data were analyzed using Kruskal-Wallis and Post hoc Mann Whitney statistical tests. Results: The mean diameter of the inhibition zone at a concentration of 25%, 50%, 75% and 100% was 3.42 mm, 4.07 mm, 4.9 mm, and 7.3 mm, respectively, and it was statistically significant (p = 0.001). Conclusion: Cocoa bean husk extract has weak anti-fungal effectiveness at concentrations of 25%, 50%, and 75%, while at 100% it has moderate effectiveness. Keywords: antifungal, Pityriasis versicolor, cocoa bean shell, well diffusion, Malassezia furfur Correspondence: Yuni Setyaningsih. Department of Parasitology, Faculty of Medicine, Universitas Pembangunan Nasional “Veteran” Jakarta. DOI: https://doi.org/10.26911/the7thicph.05.01
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '% and 2% ketoconazole' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography